Purple Biotech Ltd. American Depositary Shares

Purple Biotech will present new preclinical data on its CAPTN-3 platform of conditionally activated tri-specific antibodies at the ESMO Immuno-Oncology 2025 Congress, showcasing potential advances in cancer treatment targeting tumor immune evasion and drug resistance.

Purple Biotech received a Nasdaq letter indicating non-compliance with minimum bid price requirements, with 180 days to regain compliance by raising its stock price above $1.00 per share.

Purple Biotech closed a public offering raising $6 million upfront, with potential additional proceeds of $12 million through short-term warrant exercises. The company plans to use funds for oncology therapeutic candidate development and working capital.

Purple Biotech reported significant progress in its oncology pipeline, including promising Phase 2 results for CM24 in pancreatic cancer, advancements in the CAPTN-3 tri-specific antibody platform, and initiation of a Phase 2 study for NT219 in head and neck cancer.

Purple Biotech is advancing its novel agent NT219 into a Phase 2 study in combination with pembrolizumab or cetuximab for the treatment of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). The study aims to address the significant unmet medical need in this patient population.